NCT06406634

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Name: Clinical Trial NCT06406634
Creator: Hunan Cancer Hospital
Keywords: Hepatocellular Carcinoma, Cadonilimab, Phase 2, drug, clinical trial, China

Hunan Cancer Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatocellular Carcinoma
Drug/Device/Intervention: Cadonilimab
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Hunan Cancer Hospital
Location: Changsha, China

Timeline & enrollment

Phase: Phase 2
Start date: May 15, 2024
End date: Apr 20, 2027
Enrollment: 30 participants

Primary outcome

Objective Response Rate

Summary

This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

ICD-10 classifications

Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06406634
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06406634 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Cancer Hospital and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.